ApoB: When to Order This Test, What the Results Mean, and How to Act on Them

What does ApoB measure?

ApoB is a structural protein carried on atherogenic lipoproteins, including LDL, IDL, VLDL and lipoprotein(a). Because each particle has one ApoB molecule, its blood concentration serves as a marker of particle number. The laboratory usually reports a mass concentration in mg/dL, not a literal particle count in particles per liter. National Lipid Association consensus

LDL-C measures cholesterol carried inside LDL particles. Non-HDL-C is total cholesterol minus HDL-C and includes cholesterol carried by the other non-HDL particles. These results often move together, but they answer different questions: how much cholesterol is present versus how many particles carry it.

For example, two people can have similar LDL-C with different ApoB concentrations. This disagreement is called discordance. ApoB can help clarify the pattern without requiring the reader to infer particle number from LDL size or triglycerides alone.

When is ApoB worth ordering?

The 2026 ACC/AHA dyslipidemia guideline describes ApoB as useful for refining risk and guiding therapy after LDL-C and non-HDL-C goals are reached, particularly with diabetes, triglycerides above 200 mg/dL, or achieved LDL-C below 70 mg/dL. It can also help characterize selected lipoprotein disorders. American Heart Association guideline summary

A practical way to decide is to name the question before ordering:

ApoB should not delay treatment when the need for treatment is already clear. Before paying for it, ask what result would change the decision. If the answer is that the treatment plan would be identical at either result, its immediate value may be smaller.

What does the research on discordance show?

A 2024 UK Biobank analysis followed 293,876 adults without cardiovascular disease for a median of 11 years. People with the same approximate LDL-C, non-HDL-C or triglyceride concentration still had a range of ApoB values. ApoB supplied additional information about subsequent atherosclerotic cardiovascular events after accounting for the standard lipid measures. Sniderman et al., 2024

This explains why an acceptable-looking LDL-C does not always settle the particle-number question. It does not mean one ApoB result calculates an individual's future event probability. Blood pressure, smoking, diabetes, kidney health, age and existing cardiovascular disease still affect the overall assessment.

What is a normal ApoB level?

Laboratory categories and treatment thresholds should be labeled separately. Mayo Clinic Laboratories' adult reporting categories are:

These are the laboratory's reporting categories, not a guarantee that a value below 90 is the treatment goal for every patient. Its pediatric categories also differ. Mayo test definition

The 2024 National Lipid Association consensus proposed ApoB thresholds for considering treatment intensification:

These are proposed treatment-intensification thresholds, not population reference intervals. Identify the guideline and risk category being used; the 2026 guideline's newer risk-assessment framework should not be silently substituted into an older table. NLA consensus summary

Thus, an ApoB of 85 mg/dL can be labeled desirable by a laboratory while still prompting a treatment discussion in someone with established cardiovascular disease. That is a difference in the question being answered, not necessarily a laboratory error.

Do you need to fast, and what else should be tested?

ApoB itself generally does not require fasting. The instructions for the complete blood draw still matter: another ordered test or a follow-up triglyceride assessment may require it. Do not cancel or repeat a test solely because it was drawn after food without checking the actual order. NLA consensus

Keep the standard lipid panel. It supplies triglycerides, HDL-C and the cholesterol measures used in treatment decisions. ApoB does not replace the separate assessment of markedly elevated triglycerides.

ApoB also does not replace an Lp(a) test. Although Lp(a) particles carry ApoB, a total ApoB result cannot identify their individual contribution. The 2026 guideline recommends measuring Lp(a) at least once to identify elevated inherited risk. AHA guideline summary

What can lower ApoB?

Treatment aims to reduce atherogenic particles and cardiovascular risk. The choice depends on the baseline lipid pattern, existing disease, response and tolerability.

Food substitutions can change lipoprotein metabolism. In an 18-person controlled feeding trial in adults with insulin-resistance-related dyslipidemia, replacing saturated fat from lard with monounsaturated fat from olive oil lowered LDL-C and reduced the LDL ApoB-100 pool over four-week diet periods. This was a specific dietary substitution, not a trial showing that adding olive oil to an unchanged diet prevents heart attacks. Desjardins et al., 2024

Physical activity, weight management and dietary changes remain part of cardiovascular prevention. A particular exercise schedule should not be assigned a guaranteed ApoB reduction. Compare the actual follow-up result with the agreed treatment goal.

Medication choices have cardiovascular outcome data. Examples include:

• Ezetimibe added to a statin: In IMPROVE-IT, 18,144 patients after acute coronary syndrome received simvastatin plus ezetimibe or simvastatin alone. The seven-year primary-event estimates were 32.7% and 34.7%, respectively. Cannon et al., 2015
• A PCSK9 antibody added to statin treatment: FOURIER enrolled 27,564 patients with established atherosclerotic disease. Its primary outcome occurred in 9.8% receiving evolocumab and 11.3% receiving placebo over a median 2.2 years. Sabatine et al., 2017
• Bempedoic acid for statin-intolerant patients: CLEAR Outcomes enrolled 13,970 participants. Its primary outcome occurred in 11.7% versus 13.3% with placebo over a median 40.6 months. Nissen et al., 2023

These were trials of treatments in defined populations, with different endpoints and follow-up periods. They should not be ranked by placing the percentages side by side as if the patients were interchangeable. They also do not establish that lowering ApoB by a fixed number produces the same absolute benefit for everyone.

What if ApoB is unexpectedly low?

A low result during effective lipid-lowering treatment is different from an unexplained low result. Review the medication history, previous results, LDL-C, nutrition and relevant clinical findings before deciding what it means.

Inherited ApoB-related disorders can produce low cholesterol and ApoB, with severity varying substantially. Some affected people have few symptoms; others have problems with fat absorption, vitamin status or liver fat. Evaluation addresses the underlying condition and its effects rather than automatically trying to raise ApoB. MedlinePlus Genetics

One low number does not diagnose a genetic disorder. Likewise, medication should not be reduced solely because a result falls below an assumed population range without considering why treatment was prescribed.

When should the test be repeated?

The 2026 guideline recommends a lipid profile 4-12 weeks after starting or adjusting lipid-lowering therapy, then generally every 6-12 months. Whether ApoB is included depends on whether it is being used to guide that person's care. 2026 dyslipidemia guideline

Starting testosterone, menopausal hormone therapy or a GLP-1 medicine does not automatically create a universal ApoB testing schedule. Decide whether the additional result would change management and coordinate it with the existing lipid follow-up.

For a useful comparison, record the test date, units, medication doses, adherence and major changes since the previous draw. A trend is more interpretable when those details are available.

Practical ordering details

The test may be listed as apolipoprotein B, ApoB or ApoB-100. Mayo lists CPT code 82172. Ask for ApoB specifically if that is the intended measure; an ApoA1/ApoB ratio is a different order. Pricing and insurance coverage depend on the laboratory and plan. Mayo test definition

This is a prevention and follow-up test. Chest pressure, sudden shortness of breath or stroke symptoms such as facial droop, speech difficulty or one-sided weakness need emergency assessment without waiting for an ApoB result.

References

• National Lipid Association. ApoB expert clinical consensus. 2024.
• American Heart Association. Key points from the 2026 dyslipidemia guideline.
• Sniderman et al. ApoB discordance and cardiovascular prevention. 2024.
• Mayo Clinic Laboratories. Apolipoprotein B test definition.
• National Lipid Association. ApoB treatment-threshold summary.
• Desjardins et al. Dietary fat substitution and LDL ApoB-100 kinetics. 2024.
• Cannon et al. IMPROVE-IT. 2015.
• Sabatine et al. FOURIER. 2017.
• Nissen et al. CLEAR Outcomes. 2023.
• MedlinePlus Genetics. Familial hypobetalipoproteinemia.
• ACC/AHA and partner organizations. Dyslipidemia guideline. 2026.